These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34117554)

  • 1. Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma.
    Yugawa K; Itoh S; Yoshizumi T; Morinaga A; Iseda N; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Int J Clin Oncol; 2021 Oct; 26(10):1901-1910. PubMed ID: 34117554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8
    Miyazaki K; Morine Y; Imura S; Ikemoto T; Saito Y; Yamada S; Tokuda K; Okikawa S; Yamashita S; Oya T; Tsuneyama K; Shimada M
    Surg Today; 2021 Dec; 51(12):1985-1995. PubMed ID: 34009433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma.
    Lozzi I; Arnold A; Barone M; Johnson JC; Sinn BV; Eschrich J; Gebert P; Wang R; Hu M; Feldbrügge L; Schirmeier A; Reutzel-Selke A; Malinka T; Krenzien F; Schöning W; Modest DP; Pratschke J; Sauer IM; Felsenstein M
    Oncoimmunology; 2024; 13(1):2406052. PubMed ID: 39359389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative HALP score is a prognostic factor for intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection: association with sarcopenia and immune microenvironment.
    Toshida K; Itoh S; Nakayama Y; Tsutsui Y; Kosai-Fujimoto Y; Tomino T; Yoshiya S; Nagao Y; Harada N; Kohashi K; Oda Y; Yoshizumi T
    Int J Clin Oncol; 2023 Aug; 28(8):1082-1091. PubMed ID: 37247134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes.
    Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Mod Pathol; 2021 Apr; 34(4):798-807. PubMed ID: 33077921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
    Tian L; Ma J; Ma L; Zheng B; Liu L; Song D; Wang Y; Zhang Z; Gao Q; Song K; Wang X
    World J Surg Oncol; 2020 Nov; 18(1):303. PubMed ID: 33228682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Lymphocyte-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma.
    Yugawa K; Maeda T; Kinjo N; Kawata K; Ikeda S; Edahiro K; Edagawa M; Omine T; Kometani T; Yamaguchi S; Konishi K; Tsutsui S; Matsuda H
    J Gastrointest Surg; 2022 Jan; 26(1):104-112. PubMed ID: 34258673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: A multicentre cohort study.
    Lu LH; Zhong C; Wei W; Li SH; Mei J; Zou JW; Guo RP; Zhang YF
    Liver Int; 2021 Feb; 41(2):378-387. PubMed ID: 32562336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
    J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma.
    Lan C; Kitano Y; Yamashita YI; Yamao T; Kajiyama K; Yoshizumi T; Fukuzawa K; Sugimachi K; Ikeda Y; Takamori H; Miyanari N; Hirota M; Baba H
    Br J Cancer; 2022 Feb; 126(2):219-227. PubMed ID: 34616011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of lymphocyte-C-reactive protein ratio in patients with liver cancer: a meta-analysis.
    Shao YJ; Yu GD; Zhang X; Ran YG; Li JH
    Biomark Med; 2023 May; 17(10):497-507. PubMed ID: 37526144
    [No Abstract]   [Full Text] [Related]  

  • 14. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.
    Ye Y; Zhou L; Xie X; Jiang G; Xie H; Zheng S
    J Surg Oncol; 2009 Nov; 100(6):500-4. PubMed ID: 19697355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic roles of leptin-signaling proteins, PD-L1, and tumor-infiltrating lymphocytes in surgically-resected biliary tract cancers.
    Byeon SJ; Chang MS; Cho HJ; Park JH; Kim KH; Park JH; Choi IS; Kim W; Han DS; Ahn HS; Heo SC
    J Surg Oncol; 2023 Mar; 127(4):587-597. PubMed ID: 36367404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma.
    Mocan LP; Craciun R; Grapa C; Melincovici CS; Rusu I; Al Hajjar N; Sparchez Z; Leucuta D; Ilies M; Sparchez M; Mocan T; Mihu CM
    Cancer Immunol Immunother; 2023 Apr; 72(4):1003-1014. PubMed ID: 36251029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status.
    Yugawa K; Itoh S; Iseda N; Kurihara T; Kitamura Y; Toshima T; Harada N; Kohashi K; Baba S; Ishigami K; Oda Y; Yoshizumi T; Mori M
    Sci Rep; 2021 Mar; 11(1):5845. PubMed ID: 33712681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
    Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
    J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis.
    Gong ZJ; Cheng JW; Gao PT; Huang A; Sun YF; Zhou KQ; Hu B; Qiu SJ; Zhou J; Fan J; Yang XR
    Oncologist; 2019 Jul; 24(7):997-1007. PubMed ID: 30910867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
    Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
    Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.